Beta Bionics assumed with a Buy at Lake Street

Lake Street assumed coverage of Beta Bionics (BBNX) with a Buy rating and $30 price target The company has architected a best-in-class offering, optimal delivery channel, and R&D strategy supportive of long-term growth, according to the analyst, who does not think investors are ascribing enough value to the whole company strategy or the iLet’s “best-in-class” user simplicity and patient outcomes that “presents a one-size-fits-all ‘goldilocks’ proposition for Type 1s and Type 2s.”